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ARTICLE OPEN
'Exacerbation-free time' to assess the impact of exacerbations
in patients with chronic obstructive pulmonary disease
(COPD): a prospective observational study
L. M. Boer 1, E. W. Bischoff1, X. Borgijink2,3, J. H. Vercoulen4,5, R. P. Akkermans1,6, H. A. M. Kerstjens2,7, W. J. Assendelft1 and
T. R. Schermer1,8
COPD exacerbations are commonly quantiﬁed as rate per year. However, the total amount of time a patient suffers from
exacerbations may be stronger related to his or her disease burden than just counting exacerbation episodes. In this study, we
examined the relationship between exacerbation frequency and exacerbation-free time, and their associations with baseline
characteristics and health-related quality of life. A total of 166 COPD patients reported symptom changes during 12 months.
Symptom-deﬁned exacerbation episodes were correlated to the number of exacerbation-free weeks per year. Analysis of
covariance was used to examine the effects of baseline characteristics on annual exacerbation frequency and exacerbation-free
weeks, Spearman’s rank correlations to examine associations between the two methods to express exacerbations and the Chronic
Respiratory Questionnaire (CRQ). The correlation between exacerbation frequency and exacerbation-free weeks was −0.71 (p <
0.001). However, among frequent exacerbators (i.e., ≥3 exacerbations/year, n= 113) the correlation was weak (r=−0.25; p < 0.01).
Smokers had less exacerbation-free weeks than non-smokers (β=−5.709, p < 0.05). More exacerbation-free weeks were related to
better CRQ Total (r= 0.22, p < 0.05), Mastery (r= 0.22, p < 0.05), and Fatigue (r= 0.23, p < 0.05) scores, whereas no signiﬁcant
associations were found between exacerbation frequency and CRQ scores. In COPD patients with frequent exacerbations, there is
substantial variation in exacerbation-free time. Exacerbation-free time may better reﬂect the burden of exacerbations in patients
with COPD than exacerbation frequency does.
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INTRODUCTION
Many patients with chronic obstructive pulmonary disease (COPD)
experience exacerbations, which are deﬁned as 'sustained
worsenings of the patient’s condition from the stable state, and
beyond normal day-to-day variation, that are acute in onset and
necessitate a change in regular medication'.1 Exacerbations lead
to accelerated decline in lung function,2,3 worse health status3,4
and increased health care utilisation,5 and are the main cause of
COPD-related hospitalisations6 and mortality.7 In order to decrease
the burden of exacerbations, prevention and prompt treatment of
exacerbations are important goals in COPD patient management.8
Intervention studies in COPD often assess exacerbation
frequency (i.e., a simple count of the number of exacerbation
episodes within a certain time frame, usually a year) as a primary
outcome measure. However, measuring just the frequency of
exacerbations has limitations. First, the deﬁnitions and algorithms
used to calculate exacerbation frequency vary considerably
between studies, and the choice for a particular deﬁnition or
algorithm may inﬂuence the results substantially.9,10 Also, exacer-
bation frequency may not be the most appropriate measure in
every study. For example, interventions that focus on improving
exacerbation self-management are not so much designed to
prevent the occurrence of exacerbations, but to shorten the
duration of an exacerbation and prevent its further escalation by
early recognition and prompt treatment.11,12 Furthermore, exacer-
bation frequency is used in clinical settings to categorise COPD
severity or to select patients for particular treatment options (for
instance inhaled corticosteroids or long-acting bronchodilators),
but is only moderately related to patient-reported outcomes such
as quality of life.13,14
Duration of exacerbations is rarely used as an outcome
measure, although it can vary widely between exacerbations
and between patients.2,15–17 Donaldson and colleagues2 have
shown that prolonged exacerbation recovery time leads to poorer
health status and higher risk for subsequent exacerbations. Thus,
to focus on duration of exacerbations instead of their frequency is
an interesting concept, which may add to the understanding of
the impact of exacerbations on patients with COPD. In a recent
statement, the American Thoracic Society and European Respira-
tory Society encourage researchers to search for more patient-
centred measures, since the relationship between physicians’
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clinical goals and patients’ own priorities is often weak.18 From the
patients’ perspective it may be more appropriate to look at the
time they are free from exacerbations instead of looking at the
time they are suffering from them.
In the current study, we explored how overall ‘exacerbation-free
time’ relates to exacerbation frequency in patients with COPD. We
also explored whether exacerbation-free time is related to
patients’ baseline characteristics differently than exacerbation
frequency is, and how these two methods to express exacerba-
tions relate to patients’ health-related quality of life. We
hypothesised that exacerbation-free time is only moderately
correlated to exacerbation frequency, and that exacerbation-free
time is more strongly related to health-related quality of life than
exacerbation frequency is.
RESULTS
Of the 246 participants in the two studies, 172 (69.9%) completed
at least seventy percent of the TEXAS calls throughout their 12-
month follow-up. Six patients were marked as outliers and
excluded, leaving 166 patients for further analyses (see Fig. 1).
Table 1 shows patients’ baseline characteristics for the two
datasets combined and separately.
Correlation between exacerbation frequency and exacerbation-
free weeks
Table 2 shows the mean number of exacerbations and
exacerbation-free weeks per year. Pearson’s correlation between
exacerbation frequency and exacerbation-free weeks was −0.71
(p < 0.001, 95% CI −0.77 to −0.62; Fig. 2). In the subgroup of
infrequent exacerbators (i.e., those with <3 exacerbations/year, n
= 53), the correlation between exacerbation frequency and
exacerbation-free weeks was strong (r=−0.75, 95% CI −0.85 to
−0.61; p < 0.001). Among the frequent exacerbators (≥3 exacer-
bation/year, n= 113) the correlation was weak (r=−0.25, 95% CI
−0.42 to −0.07; p < 0.01).
Baseline characteristics in relation to exacerbation frequency and
exacerbation-free weeks
Of the baseline characteristics analysed, only Medical Research
Council (MRC) category was related to exacerbation frequency
(main effect: p= 0.008). Table 3 shows the associations between
MRC categories and exacerbation frequency and exacerbation free
time. Patients in MRC category 1 (i.e., MRC score 0 or 1) had a
signiﬁcantly lower mean exacerbation frequency than patients in
MRC category 3 (mean 3.4 ± 2.2 vs. 4.5 ± 2.0 exacerbations/year; β
=−1.258, p= 0.006). No statistically signiﬁcant difference
between patients in MRC category 2 (mean 4.2 ± 1.8 exacerba-
tions/year) and patients in MRC category 3 was observed (β=
−0.320, p= 0.464). Exacerbation-free weeks were also related to
baseline MRC (main effect: p= 0.043). Patients in MRC category 1
had signiﬁcantly more exacerbation-free weeks than patients in
MRC category 3 (mean 36.4 ± 12.9 vs. 28.6 ± 12.6 exacerbation-free
weeks/year; β= 6.831, p= 0.014). No statistically signiﬁcant
difference between patients in MRC category 2 (mean 32.6 ±
11.7 exacerbation-free weeks/year) and patients in MRC category
3 was observed (β= 3.248, p= 0.228). Patients who were current
smokers had less exacerbation-free time than patients who had
quit smoking or had never smoked (mean 29.3 ± 13.3 vs. 34.7 ±
12.1 exacerbation-free weeks/year; β=−5.709, p= 0.014).
Exacerbation frequency and exacerbation-free time in relation to
health-related quality of life
Table 4 shows that Spearman’s correlations between exacerbation
frequency and CRQ scores at 12-month follow-up were weak. In
contrast, correlations between exacerbation-free weeks and CRQ
scores showed that having more exacerbation free time was
related to a higher CRQ total score (r= 0.216, p= 0.034), better
mastery (r= 0.217, p= 0.034), and less fatigue (r= 0.232, p=
0.023).
DISCUSSION
Summary of the main ﬁndings
In this study we explored how COPD patients’ overall
exacerbation-free time relates to the frequency of their exacerba-
tions, analysed associations between baseline characteristics and
these two ways of quantifying exacerbations, and assessed which
of the two quantiﬁcations shows the strongest association with
patients’ HRQoL. In research as well as in daily practice, looking at
exacerbation-free time may be a valuable addition to exacerbation
Fig. 1 Flow chart of selection of patients for the current analysis
from the two original studies. Abbreviation: TEXAS Telephonic
EXacerbation Assessment System
Table 1. Patient characteristics at baseline, presented in number (%)
or mean (SD)
Total sample
(n= 166)
Primary care-
RCT20 (n= 100)
Secondary care-
cohort study21
(n= 66)
Patient characteristics
Male (%) 119 (71.7) 67 (67.0) 52 (78.8)
Age (SD) 66.0 (8.6) 65.7 (8.8) 66.3 (8.4)
Current smokers (%) 45 (27.1) 35 (35.0) 10 (15.2)
BMI (SD) 26.3 (4.3) 26.6 (4.6) 25.9 (3.6)
FEV1% predicted
(SD)
60.3 (18.0) 64.5 (16.7) 53.8 (18.2)
Obstruction severity (GOLD)
Mild (%) 23 (13.9) 17 (17.0) 6 (9.1)
Moderate (%) 95 (57.2) 63 (63.0) 32 (48.5)
Severe (%) 41 (24.7) 18 (18.0) 23 (34.8)
Very severe (%) 7 (4.2) 2 (2.0) 5 (7.6)
MRC dyspnoea scale (n= 162)
Category 1 (%) 63 (38.9) 37 (37.4) 26 (41.3)
Category 2 (%) 60 (37.0) 44 (44.4) 16 (25.4)
Category 3 (%) 39 (24.1) 18 (18.2) 21 (33.3)
FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic
Obstructive Lung Disease, BMI body mass index, MRC Medical Research
Council
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frequency when assessing the impact of exacerbations in patients
with COPD, because we observed substantial variation in
exacerbation-free time, particularly among patients who have
frequent (i.e., three or more) exacerbations per year. We also
found that patients who are current smokers have signiﬁcantly
less exacerbation-free time but not a higher annual exacerbation
frequency than patients who do not smoke (29.3 vs. 34.7
exacerbation-free weeks, respectively). Our results showed no
association between exacerbation frequency and COPD patients’
HRQoL, whereas more exacerbation-free time was related to
better CRQ mastery, CRQ fatigue, and CRQ total scores.
Comparison with existing literature
While several studies have examined variation in exacerbation
length,15,16 time to next exacerbation,15 time to ﬁrst hospitalisa-
tion,19 and the impact of interventions on exacerbation
length,12,20 few studies in COPD have used exacerbation time
per year (or the inverse, i.e. exacerbation-free time) as outcome
measure. Donaldson et al.2 have examined the effect of
exacerbation recovery time on health status. Our results seem
consistent with their ﬁnding that longer exacerbation recovery
time led to worse scores on the St. George Respiratory
Questionnaire (0.20 units per one day longer recovery). Still, our
ﬁndings differ on other aspects. For instance, our patients
reported more time with exacerbations than the population of
Donaldson’s London Cohort Study (35% vs. 9% of observation
period, respectively).2 Also, our median exacerbation frequency is
4.1, whereas Donaldson et al. reported a median of 2.1. We have
no clear explanation for these differences, since we had a
heterogeneous study sample with a higher mean FEV1% predicted
than the London cohort (60.3% vs. 45.7%, respectively) and we
used the same deﬁnition of exacerbation.2 One difference
between both studies is that the London Cohort Study made
use of daily diaries where we made use of two-weekly telephone
calls. Although this may account for some of the discrepancy in
the time spent in exacerbations, our previous study demonstrated
TEXAS to be a valid measure to assess exacerbation frequency.21
Our mean exacerbation frequency does correspond with the
ﬁndings of Erdal et al.,22 who found a median exacerbation
frequency of four in their hospital-recruited COPD patients.
Supporting smoking cessation is one of the key elements in the
treatment of COPD,8 although the evidence for positive effects of
smoking cessation on exacerbation frequency is weak.23 We found
a statistically and clinically signiﬁcant difference in exacerbation-
free weeks between current smokers and ex-smokers that
emphasises the importance of smoking cessation in patients with
COPD.
We found no relationship between exacerbation frequency and
HRQoL, which may seem in contrast to previous literature.3,4
However, these studies all used the SGRQ. This questionnaire
measures several aspects of health status,24 but not speciﬁcally
health-related quality of life.25 Our ﬁndings are in line with a
previous study from our group, where we used the Nijmegen
Clinical Screening Instrument to measure health status.14
Strengths and limitations
A strength of this study was the large and heterogeneous study
sample, derived from both a primary care and a hospital setting.
Also, the collection of exacerbation-related data was very
structured at the same date and time every week, with no
possibility to skip questions, due to the use of our automated
TEXAS system. However, although TEXAS has proven to be a valid
system to capture exacerbations with two-weekly calls,21 for the
measurement of exacerbation-free time, a timeframe of two
weeks may not be ideal. Although the correlation between weekly
and two-weekly data was very high (r= 0.90), we would have
preferred more detailed measurement to assess exacerbation-free
time, ideally using daily registrations. Nevertheless, the questions
asked by TEXAS (see Appendix) explicitly refer to symptoms
experienced during the last two weeks. Another limitation was
that HRQoL was only assessed in the primary care cohort.
Inevitably, our approach and interpretation of missing data
from calls will have inﬂuenced the number of exacerbations we
found, as is the case in all studies.9,10 This limitation actually pleas
in favour of using exacerbation-free time as an outcome measure;
it seems more easy to establish when an exacerbation is not
Table 2. Self-reported exacerbation frequency and number of exacerbation-free weeks, presented in mean (SD) and number (%) of patients with
frequent exacerbations (≥3/year)
Total sample (n= 166) Primary care-RCT20 (n= 100) Secondary care-cohort study21 (n= 66)
Number of TEXASa calls (SD) 21.3 (1.9) 21.0 (1.8) 21.6 (1.9)
Exacerbation frequency/year (SD) 4.0 (2.1) 4.0 (2.2) 4.1 (1.9)
Exacerbation-free weeks/year (SD) 33.4 (12.5) 33.8 (13.3) 32.8 (11.3)
Frequent (≥3) exacerbators (%) 113 (68.1) 68 (68.0) 45 (68.2)
TEXAS Telephonic EXacerbation Assessment System
aCalls were made every fortnight during the 12-month observation period
Fig. 2 Scatter plot of exacerbation frequency (number of exacerba-
tions/year) against exacerbation-free time (exacerbation-free weeks/
year). Each dot represents one patient (n= 172). Solid dots: patients
were considered as outliers and excluded from further analyses if
they reported exacerbations for more than 85% of their follow-up
time (n= 6). Dotted line: the study population was divided in
infrequent (i.e., <3 exacerbations/year) and frequent (≥3 exacerba-
tions/year) exacerbators, based on previous research30
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present than to establish when a new episode has exactly started.
Furthermore, instead of introducing yet another instrument, we
are proposing to use a new outcome that can be assessed with
data that has already been collected in previous studies. Most
studies using a symptom-based deﬁnition of exacerbations assess
respiratory symptom changes with daily or weekly diaries.
Exacerbation-free time can be calculated with these diaries also,
so it would be an easy measure to add to analyses and published
reports.
In conclusion, our ﬁndings indicate that exacerbation-free time
and exacerbation frequency are two distinct quantiﬁcations to
express exacerbations in patients with COPD, especially in
frequent exacerbators. This, and the observed association
between current smoking and exacerbation-free time is relevant
for research as well as clinical practice. Although the correlation
was weak, exacerbation-free time was associated with HRQoL,
whereas exacerbation frequency was not. This supports our
proposition that exacerbation-free time is a more patient-
centred outcome than exacerbation frequency is. Further research
is needed to examine if overall exacerbation-free time may be a
sensitive measure to capture the more subtle effects of interven-
tions aimed at improving self-management and prompt treatment
of exacerbations. Health care providers should be aware that the
time a patient suffers from exacerbations can vary widely among
patients, may increase when the patient is an active smoker, and
negatively inﬂuences COPD patients’ disease burden in terms of
health-related quality of life.
METHODS
Study design and population
Secondary analyses were performed on data from two studies that were
previously conducted by our research group. The ﬁrst study was a 12-
month prospective cohort study in an outpatient setting in which
exacerbation-related data were collected to validate the Telephonic
EXacerbation Assessment System (TEXAS), an automated telephone
system for assessing exacerbations in prospective studies.21 Recruitment
took place in the Radboud university medical center in Nijmegen, the
Netherlands in 2006 and 2007. Inclusion criteria relevant to the present
analysis were: spirometry-conﬁrmed COPD according to the GOLD criteria
(i.e. ratio of post-bronchodilator forced expiratory volume in 1 s (FEV1) to
forced vital capacity (FVC) <0.70); percentage of predicted FEV1 between
30 and 80%; and age ≥40. Patients with a severe comorbid condition with
a reduced life expectancy were excluded.21
The second study was a 24-month, three-arm, multi-centre randomised
controlled trial (RCT) in a primary care setting in which a COPD self-
management programme was compared with programmed routine
monitoring and usual care.20 Recruitment took place in 15 general
practices in the eastern part of the Netherlands between 2004 and 2006.
Inclusion criteria were post-bronchodilator FEV1/FVC <0.70 and age ≥35.
Exclusion criteria were percentage of predicted FEV1 <30%; treatment by a
chest physician; severe comorbid conditions with a reduced life
expectancy; inability to communicate in the Dutch language (Clinical trials
registration NCT00128765).20
For the present study, the two data sets were combined, leading to a
mixed population of primary and secondary care patients with mild to
severe COPD (Fig. 1).
Methods were performed in accordance with relevant regulations and
guidelines. Both studies were approved by the Medical Ethics Committee
(Arnhem-Nijmegen, the Netherlands; approval numbers 2006/081 and
2004/249, respectively). All patients gave written informed consent.
Measurements and deﬁnitions
Sex, age, smoking history, body mass index, lung function, and the Medical
Research Council (MRC) dyspnoea scale26,27 were assessed at baseline in
both studies. The MRC dyspnoea scale is a single-item scale that measures
functional limitations due to dyspnoea ranging from 0 (‘I never get
breathless’) to 5 (‘I am too breathless to leave the house’).
Health-related quality of life (HRQoL) at baseline and 12 months was
measured in the primary care RCT20 only, using the Chronic Respiratory
Questionnaire (CRQ) self-administered standardised version.28 The CRQ is a
20-item questionnaire with four sub-domains: dyspnoea, fatigue, emo-
tional function, and mastery. Items are scored on a seven-point scale, with
higher scores indicating better HRQoL. A total score as well as separate
domain scores are calculated.
Annual exacerbation frequency and exacerbation-free time. In both studies
TEXAS21 was used to collect data on respiratory symptom aggravations.
TEXAS called the patients every fortnight, asking standardised questions
about changes in respiratory symptoms, respiratory medication use, and
Table 3. Associations between baseline characteristics and exacerbation frequency and exacerbation-free weeks, analysed with two separate
univariable analysis of covariance models (n= 166)
Exacerbation frequency Exacerbation-free weeks
β 95% CI p β 95% CI p
Male −0.230 −0.979 0.518 0.544 −2.151 −6.752 2.450 0.357
Age −0.032 −0.072 0.009 0.121 0.026 −0.221 0.273 0.837
FEV1% predicted −0.002 −0.021 0.017 0.866 0.060 −0.056 0.177 0.309
Current smoker 0.070 −0.670 0.809 0.853 −5.709 −10.252 −1.166 0.014
BMI −0.032 −0.110 0.045 0.406 0.129 −0.345 0.602 0.591
MRC category 1a −1.258 −2.144 −0.337 0.006 6.831 1.390 12.271 0.014
MRC category 2a −0.320 −1.182 0.542 0.464 3.248 −2.049 8.544 0.228
β unstandardised Beta coefﬁcients, CI conﬁdence interval, FEV1 forced expiratory volume in 1 s, BMI body mass index, MRC Medical Research Council
aMRC category 3 (i.e., MRC score 3, 4 or 5) as reference category
Bold values are p-values below 0.05
Table 4. Spearman’s rank correlation coefﬁcients (r) of exacerbation
frequency and exacerbation-free weeks with disease-speciﬁc HRQoL at
12-month follow-up (primary care cohort only, n= 96)
Exacerbation
frequency
Exacerbation-
free weeks
Mean score (SD) r p r p
CRQ total 5.3 (0.80) −0.052 0.614 0.216 0.034
CRQ emotions 5.4 (0.97) −0.028 0.784 0.166 0.105
CRQ mastery 5.0 (0.66) −0.035 0.738 0.217 0.034
CRQ fatigue 5.0 (1.17) −0.069 0.506 0.232 0.023
CRQ dyspnoea 5.8 (1.15) −0.079 0.446 0.185 0.071
CRQ Chronic Respiratory Questionnaire, HRQoL health-related quality of life
Bold values are p-values below 0.05
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contacts with health care professionals in the previous two weeks (see
Appendix 1). For every fortnight, an algorithm was used to calculate
whether or not an exacerbation had occurred. Previously, in the
prospective cohort study we established that exacerbation frequency
could be measured validly using TEXAS every fortnight.21 To verify that the
two-weekly TEXAS data could be converted to exacerbation-free weeks,
the weekly conversion was correlated to the weekly paper diary cards that
patients completed in that study to register exacerbation-related data. The
correlation coefﬁcient was very high (Pearson’s r= 0.90, 95% CI 0.86–0.94;
p < 0.001).
In the absence of scientiﬁc consensus on a symptom-based deﬁnition,
we adopted the most commonly used deﬁnition9 to determine whether or
not exacerbations had occurred in a particular fortnight: a change for at
least two consecutive days in two or more major symptoms (dyspnoea,
sputum purulence, sputum amount), or a change in any one major
symptom plus any one or more minor symptoms (common cold, wheeze,
sore throat, and cough).15,29 After that, exacerbation-free time was deﬁned
as the inverse of exacerbation presence, i.e. the number of weeks without
exacerbations (as deﬁned above).
Statistical analyses
To create two comparable data sets to merge into one, only the data from
the ﬁrst 12 months of the 24-month RCT20 were used. Patients were
excluded from analysis if during the 12-month time frame <70% of TEXAS
calls had been completed. For both exacerbation frequency and number of
exacerbation-free weeks a mean number per year was calculated. Because
TEXAS does not allow skipping questions, missing items within calls were
not present. A call in which an exacerbation was scored (‘exacerbation
positive’ call) was counted as a new episode when the previous call was
‘exacerbation negative’. When the previous call was ‘exacerbation positive’
the subsequent positive call was marked as an extension of the same
exacerbation episode. When due to one or more missing calls it was
unclear whether an ‘exacerbation positive’ call marked a new episode or
was part of the previous exacerbation, it was marked as the same
exacerbation episode.
A 99% conﬁdence interval (CI) around the regression line was drawn in a
scatter plot of exacerbation frequency (i.e., number of exacerbations/year)
against exacerbation-free time (i.e., exacerbation-free weeks/year). Patients
were considered as outliers and excluded from further analyses if they
reported exacerbations for more than 85% of their follow-up time (see Fig.
2). To examine the relationship between exacerbation frequency and
exacerbation-free weeks, two-sided Pearson’s correlation coefﬁcients were
calculated for the combined study population. Because the scatter plot
showed an increasing variance in the number of exacerbation-free weeks
when the annual exacerbation frequency increased, in a subgroup analysis,
the study population was divided in infrequent (i.e., <3 exacerbations/year)
and frequent (≥3 exacerbations/year) exacerbators. The cut-off was set at
three exacerbations per year based on previous research.30 Two-sided
Pearson’s correlations between exacerbation frequency and exacerbation-
free weeks were calculated for each subgroup.
Next, associations between baseline characteristics (age, gender,
smoking status, percentage of predicted FEV1, body mass index, and
MRC dyspnoea score) and exacerbation frequency and exacerbation-free
weeks were examined using two separate analyses of covariance models.
Score 0, 4, and 5 of the MRC dyspnoea scale were infrequently reported
(four, ﬁve, and three times, respectively). For statistical purposes, MRC
scores 0 and 1 were recoded into category 1, score 2 into category 2 and
scores 3, 4, and 5 into category 3. Finally, associations between
exacerbation frequency and exacerbation-free weeks and the CRQ (total
score and sub-domain scores) at 12 months of follow-up were examined
using two-sided Spearman’s rank correlations.
P < 0.05 was considered statistically signiﬁcant. IBM SPSS Statistics 22©
was used for all analyses.
Data availability
The datasets generated during and/or analysed during the current study
are available from the corresponding author on reasonable request.
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